The US FDA Clears Abbott’s Two New Over-The-Counter Continuous Glucose Monitoring Systems
Shots:
- The US FDA has granted clearance to 2 OTC CGM systems, Lingo & Libre Rio, based on FreeStyle Libre sensing technology
- The Lingo system, a biowearable to improve overall health & wellness in ≥18yrs. users, track glucose using a biosensor worn for 14 days on the upper arm & displays the data on a smartphone generating insights on diet, exercise & stress to develop healthy habits & improve overall well-being
- The Libre Rio system, with a range of 40-400mg/dL intended for T2D in ≥18yrs. non-insulin users measure glucose levels using a biosensor worn on the back of the arm for up to 15 days. Clinical results & RWE have shown its ability to improve glucose control, lowering HbA1c & reducing diabetes-related hospital admissions
Ref: Abbott | Image: Abbott
Related News:- Abbott’s AVEIR Dual Chamber Leadless Pacemaker System Gains CE Mark to Treat Abnormal or Slow Heart Rhythms
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
